Cautious welcome for new glaucoma guidelines

Article

New guidelines, designed to improve the management and diagnosis of chronic open angle glaucoma (COAG) and ocular hypertension have received a cautious commendation from the ophthalmic community.

New guidelines, designed to improve the management and diagnosis of chronic open angle glaucoma (COAG) and ocular hypertension have received a cautious commendation from the ophthalmic community. However, there are concerns about implementation.

“While the guidelines provide much-needed clarity on the diagnosis and management of glaucoma, implementation of the guidance will mean hundreds of thousands of additional hospital visits, most of which will be unnecessary. Optometrists are well- placed to provide a solution to this problem, with appropriate training,” reported Geoff Robertson, AOP professional advisor.

The guidelines, issued by NICE contain a key recommendation that patients should be formally diagnosed by a healthcare professional with a specialist qualification using techniques which few optometrists currently perform (applanation tonometry, gonioscopy and pachymetry). In order to comply with the new guidelines, optometrists will have to refer these patients to a specialist for a formal diagnosis and monitoring. This would normally mean the patient would need to be referred to hospital rather than being seen in the community.

According to The Association of British Dispensing Opticians, The Association of Ophthalmologists, The Association of Optometrists, The College of Optometrists, The Federation of Ophthalmic and Dispensing Opticians and The General Optical Council this would represent an increase of 10% over the 5 million ophthalmic outpatients episodes provided in 2007-8. The General optical Council said the Hospital Eye Service is a highly specialised part of the eye care sector but it will struggle to cope with such a large increase with inevitable consequences for waiting lists and appointment intervals. It may that under the Any Willing Provider programme ophthalmologists working in the community would be able to take on some of any extra workload but this will probably not solve the problem.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.